Full Press Release Details
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025
Successful completion of the obesity End-of-Phase 2 meeting with the FDA
Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning Q4 2024
Cash, cash equivalents and short-term investments of $139.4 million on September 30, 2024
Webcast to be held today, November 12, 2024, at 8:30 a.m. ET
GAITHERSBURG, MD - November 12, 2024 - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.
"In the third quarter, we reached several important milestones, most notably the completion of enrollment in the Phase 2b IMPACT trial of pemvidutide in MASH, positioning us to report top-line efficacy data in the second quarter of 2025," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "Further, we successfully completed our End-of-Phase 2 meeting with the FDA for the pemvidutide Phase 3 obesity program, gaining agreement on the design of the pivotal studies as well as the measures of efficacy and safety."
Dr. Garg continued, "The Phase 3 program is designed to leverage the key attributes of pemvidutide, including the effects of balanced GLP-1/glucagon dual agonism in subjects with overweight and obesity. The program will include four pivotal trials with a primary efficacy endpoint of weight loss and will evaluate the effects of pemvidutide on principal co-morbidities of obesity, including elevated serum lipids and excess liver fat. The program will also assess the preservation of lean mass and its impact on subjects at risk for loss of physical function and other complications of sarcopenia."
"At the 60th Annual Meeting of the European Association for the Study of Diabetes, we presented compelling data from our Phase 2 MOMENTUM trial of pemvidutide in obesity, which highlighted its class-leading preservation of lean mass and preferential reduction in visceral adipose tissue, both of which are important differentiators for pemvidutide," said Scott Harris, M.D., Chief Medical Officer of Altimmune. "We also remain on-track to submit an IND application this quarter for the first of up to three additional indications for pemvidutide, with the trial expected to initiate in the first half of 2025."
Dr. Garg concluded, "The data we have generated to date, coupled with the multiple key inflection points on the horizon, give us confidence that 2025 will be a transformational year for pemvidutide, and for Altimmune."
Recent Highlights and Anticipated Milestones:
Metabolic Dysfunction-Associated Steatohepatitis (MASH):
Additional Indications for Pemvidutide:
Financial Results for the Three Months Ended September 30, 2024:
Conference Call Information:
| Date: | Tuesday, November 12, 2024 |
| Time: | 8:30 a.m. Eastern Time |
| Webcast: | To listen, the conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors . |
| Dial-in: | To participate or dial-in, register here to receive the dial-in numbers and unique PIN to access the call. |
Following the conclusion of the call, the webcast will be available for replay on the Investor Relations (IR) page of the Company's website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial.
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Forward-Looking Statement
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of the IMPACT trial data readout, the timing of the planned End-of-Phase 2 FDA meeting, the timing of the planned IND submissions for pemvidutide, the timing of key milestones for any of our clinical assets, and the prospects for the utility of, regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K and our other filings with the SEC, which are available at www.sec.gov.
| Vipin Garg |
| President and Chief Executive Officer |
| Phone: 240-654-1450 |
| ir@altimmune.com |
| Lee Roth Burns McClellan |
| Phone: 646-382-3403 |
| lroth@burnsmc.com |
| Julia Weilman Burns McClellan |
| Phone: 646-732-4443 |
| jweilman@burnsmc.com |
| Danielle Cantey |
| Inizio Evoke, Biotech |
| Phone: 619-826-4657 |
| Danielle.cantey@inizioevoke.com |
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per-share amounts)
| September 30, | December 31, | |||||
| 2024 | 2023 | |||||
| (Unaudited) | ||||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 31,474 | $ | 135,117 | ||
| Restricted cash | 42 | 41 | ||||
| Total cash, cash equivalents and restricted cash | 31,516 | 135,158 | ||||
| Short-term investments | 107,906 | 62,698 | ||||
| Accounts and other receivables | 428 | 1,111 | ||||
| Income tax and R&D incentive receivables | 2,912 | 3,742 | ||||
| Prepaid expenses and other current assets | 2,997 | 6,917 | ||||
| Total current assets | 145,759 | 209,626 | ||||
| Property and equipment, net | 446 | 651 | ||||
| Other assets | 1,659 | 363 | ||||
| Total assets | $ | 147,864 | $ | 210,640 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 1,133 | $ | 2,070 | ||
| Accrued expenses and other current liabilities | 7,505 | 10,073 | ||||
| Total current liabilities | 8,638 | 12,143 | ||||
| Other noncurrent liabilities | 5,849 | 4,398 | ||||
| Total liabilities | 14,487 | 16,541 | ||||
| Commitments and contingencies | ||||||
| Stockholders' equity: | ||||||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 71,124,407 and 70,677,400 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 7 | 7 | ||||
| Additional paid-in capital | 676,425 | 665,427 | ||||
| Accumulated deficit | (538,210) | (466,331) | ||||
| Accumulated other comprehensive loss, net | (4,845) | (5,004) | ||||
| Total stockholders' equity | 133,377 | 194,099 | ||||
| Total liabilities and stockholders' equity | $ | 147,864 | $ | 210,640 |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per-share amounts)
| Three Months Ended | Nine Months Ended | |||||||||||
| September 30, | September 30, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Revenues | $ | 5 | $ | 362 | $ | 15 | $ | 389 | ||||
| Operating expenses: | ||||||||||||
| Research and development | 19,803 | 18,388 | 62,445 | 48,890 | ||||||||
| General and administrative | 4,969 | 4,514 | 15,876 | 13,805 | ||||||||
| Total operating expenses | 24,772 | 22,902 | 78,321 | 62,695 | ||||||||
| Loss from operations | (24,767) | (22,540) | (78,306) | (62,306) | ||||||||
| Other income (expense): | ||||||||||||
| Interest expense | (6) | (29) | (8) | (33) | ||||||||
| Interest income | 1,910 | 1,884 | 6,505 | 5,387 | ||||||||
| Other income (expense), net | 18 | 14 | (70) | 146 | ||||||||
| Total other income (expense), net | 1,922 | 1,869 | 6,427 | 5,500 | ||||||||
| Net loss | (22,845) | (20,671) | (71,879) | (56,806) | ||||||||
| Other comprehensive income - unrealized gain on short-term investments | 347 | 56 | 159 | 103 | ||||||||
| Comprehensive loss | $ | (22,498) | $ | (20,615) | $ | (71,720) | $ | (56,703) | ||||
| Net loss per share, basic and diluted | $ | (0.32) | $ | (0.39) | $ | (1.01) | $ | (1.10) | ||||
| Weighted-average common shares outstanding, basic and diluted | 71,084,787 | 53,633,354 | 70,927,222 | 51,495,957 |